MRSA specific scores promote overuse of anti-MRSA antibiotics
M. Restrepo (San Antonio, United States of America), N. Borsa (Milan, Italy), M. Carugati (Milan, Italy), N. Soni (San Antonio, United States of America), A. Rodriguez (Tarragona, Spain), F. Blasi (Milan, Italy), S. Aliberti (Milan, Italy), G. Investigators (San Antonio, United States of America)
Source: International Congress 2019 – Pneumonia in 2019: antimicrobial resistance, cardiovascular complications and diagnosis
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Restrepo (San Antonio, United States of America), N. Borsa (Milan, Italy), M. Carugati (Milan, Italy), N. Soni (San Antonio, United States of America), A. Rodriguez (Tarragona, Spain), F. Blasi (Milan, Italy), S. Aliberti (Milan, Italy), G. Investigators (San Antonio, United States of America). MRSA specific scores promote overuse of anti-MRSA antibiotics. 3303
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Staphlococcus aureus : susceptibility to antibacterial drugs and rate of MRSASource: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006
Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004
Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018
Treatment of difficult Gram-positive infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=113 Year: 2004
Biological resistance to beta-lactamic antibiotics in patients with respiratory infection in the prediction of efficiency of antibacterial therapy Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020
The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Long-term, low-dose azithromycin treatment reduces the prevalence of staphylococcus aureus , but selects for macrolide resistance in Danish CF-patients Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007
Treatment challenges in methicillin resistant Staphylococcus aureus infections Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002
Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006
Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia Source: Eur Respir J 2007; 30: 1234-1235 Year: 2007
Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012
Epidemiological impact of antibiotic use/misuse in the community Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=165 Year: 2004
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011
Impact of antibiotic consumption in the evolution of respiratory pseudomonas antibiotic resistance Source: Eur Respir J 2006; 28: Suppl. 50, 787s Year: 2006